PTC THERAPEUTICS, INC. 4

Insider Michael Schmertzler, through Section Six Partners, L.P., sold a total of 25,000 shares of PTC Therapeutics (PTCT) common stock for roughly $1.8 million under a Rule 10b5‑1 plan.

On August 19–20, 2026, Michael Schmertzler, reporting as an insider of PTC Therapeutics, Inc., reported a series of open‑market sales of PTCT common stock executed pursuant to a pre‑established Rule 10b5‑1 trading plan through Section Six Partners, L.P., an investment partnership of which he is both a general and limited partner. The transactions consisted of five sale blocks totaling 25,000 shares at weighted average prices between approximately $70.78 and $73.67 per share, generating estimated proceeds of about $1.8 million. Following these plan‑based dispositions, the partnership (for which Schmertzler disclaims beneficial ownership except for his pecuniary interest) reported indirect ownership of 1,361,594 shares of PTCT common stock. The filing characterizes the trades as routine 10b5‑1 executions but still represents a meaningful liquidity event in dollar terms relative to typical insider activity.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001288952-26-000004

Alert Tier

6